AAV9-MyoDys-45-55

N/A

Report date: 2025/01/26 18:11:31

Base Information

Drug NameAAV9-MyoDys-45-55
Drug Alias NameCRISPR/Cas9-based DMD gene editing therapy (MyoGene Bio/University of California/University of Washington)MyoDys-45-55
ClassificationBiologics
Mechanisms of ActionDystrophin gene transference
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of CaliforniaMyoGene Bio LLCUniversity Of Washington
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A